Business Development

Business Development opportunities at Cellectis provide access to a unique set of programs and technologies.

Therapy-focused programs

Through its subsidiary Cellectis Genome Surgery, Cellectis is developing several therapy-focused programs for treating formerly incurable monogenic diseases and chronic DNA-virus infections. All these projects are in the pre-clinical phase.
Cellectis is seeking partners to collaborate within programs focusing on:

• repairing the defective gene that causes sickle cell anemia;

• reducing the viral load, by striking the viral DNA in infected cells, and therefore enabling the patient's immune system to combat the virus, whether HIV, hepatitis B or herpes.

  
  

Licenses

Cellectis licenses out its proprietary technologies providing:

• access to its meganuclease engineering platform in the context of partnerships for developing new therapy-focused programs, cell lines, or for agricultural biotechnology;

• access to gene replacement and homologous recombination patents, in order to create and use knock-in cells and animals.

Products

Research kits are marketed by its subsidiary Cellectis bioresearch to enable the fast and effortless engineering of stable cell lines for applications in drug screening, biologics productions, and cellular model creation.